We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : MLSC Blood decontaminant recieves patent!!! -- Ignore unavailable to you. Want to Upgrade?

To: Cindy Powell who wrote (191)1/17/2001 1:03:44 PM
From: Cindy Powell  Read Replies (1) | Respond to of 196
Study Validates Microbicidal Effectiveness of Medical Discoveries, Inc. Novel Drug, 'MDI-P'
Peer-Reviewed Research Paper Details Sterilization Effectiveness
SALT LAKE CITY, Jan. 10 /PRNewswire/ -- A new study on the microbe-killing properties of MDI-P, using four microorganisms that are difficult to eradicate in the hospital environment, has been completed at the Infectious Diseases Section of the Stratton VA Medical Center in Albany, New York.

The infectious diseases research group, headed by Aldona Baltch, M.D., found that MDI-P is a highly effective microbicide for the organisms studied. The microbicidal effect of MDI-P is very rapid and it retains high microbicidal activity even in the presence of 50% human blood serum. There are no obvious adverse effects on the tissues of mice injected intravenously with MDI-P and preliminary results suggest that the microbicidal activity of MDI-P is relatively stable. The results of this study suggest that MDI-P may be useful for disinfection of inanimate surfaces, cold sterilization of medical devices, antisepsis, and irrigation therapy for wounds and ulcers.

The findings of Dr. Baltch's group have been published in ``The American Journal Of Infection Control'' (AJIC 2000;28:251-7), the official journal of the Association for Professionals in Infection Control and Epidemiology, Inc. (APIC). ``AJIC'' covers key topics and issues in the field of infection control, with peer-reviewed articles ranging from practical, clinically applicable topics to original, cutting-edge scientific research. ``AJIC'' is a highly respected resource on infection control, epidemiology, quality assurance, occupational health, and disease prevention and is widely read by infection control professionals, including physicians, nurses, and epidemiologists.

In addition to the ``AJIC'' paper, Dr. Baltch's work on MDI-P has been published in the abstracts of, and presented at, the 97th and 98th Annual Meetings of The American Society of Microbiology. The research was supported by Medical Discoveries, Inc. and, in part, by the Research Service of the Veterans Administration.

The four microorganisms used in the studies were Pseudomonas aeruginosa, Staphylococcus aureus, and Legionella pneumophila, all bacteria, and Candida albicans, a yeast (a type of fungus). These organisms were studied because each is an important human pathogen, is commonly found in the hospital environment, and presents difficulties with regard to eradication in that environment.

The microbicidal activity of MDI-P against these organisms was tested at several concentrations and in the presence and absence of human blood serum. In addition, the effects of MDI-P on the morphology of the microbial cells were studied by Gram staining and transmission electron microscopy. Morbidity, mortality, and tissue toxicity were also studied using laboratory mice.

In addition to its microbicidal properties, MDI-P was found to be inexpensive, simple to prepare, apparently harmless to inanimate surfaces, and without significant odor. It retained its microbicidal activity over a pH range from approximately 6.5 to 9. Dr. Baltch's paper also cited other published research regarding the microbicidal activity of MDI-P against bacteria, yeast, and viruses. She called for further testing in order to establish the most useful applications and the exact chemical composition of MDI-P.

MDI-P is a proprietary new (novel) preparation produced by Medical Discoveries, Inc. (MDI) and protected directly or indirectly by eight original U.S. patents, covering both the production and application of the product.

Formed in 1991, Medical Discoveries, Inc. is a publicly traded (OTC: MLSC - news) development-stage biopharmaceutical research company (as defined in SFAS No. 7) engaged in the research, development and validation of a new class of drugs, based upon the company's patented and proprietary electrolysis technologies. MDI is developing active anti-viral (HIV/AIDS), anti-bacterial and anti-fungal agents for a variety of applications. MDI is currently attempting to secure capital commitments to finance continued research and testing of its novel drugs and technologies.

Information in this press release relating to the potential of MDI and MDI-P constitutes forward-looking statements. Actual results in future periods may differ materially from the forward-looking statements because of a number of risks and uncertainties, including but not limited to MDI's unproved products, capital requirements, competition, and governmental regulation. Additional information about these and other factors that could affect MDI's business is set forth in MDI's 1999 Annual Report on Form 10-KSB and other filings with the Securities and Exchange Commission.

SOURCE: Medical Discoveries, Inc.
Wednesday January 10, 10:36 am Eastern Time
Press Release
SOURCE: Medical Discoveries, Inc.